Valuation : Supernus Pharmaceuticals, Inc.

Market Cap 2.42B 2.09B 1.97B 1.79B 3.36B 231B 3.37B 23.45B 9.02B 118B 9.09B 8.89B 372B P/E 2026 *
-208x
P/E 2027 * 33.9x
Enterprise Value 2.42B 2.09B 1.97B 1.79B 3.36B 231B 3.37B 23.45B 9.02B 118B 9.09B 8.89B 372B EV / Sales 2026 *
2.73x
EV / Sales 2027 * 1.76x
Free-Float
95.67%
Yield 2026 *
-
Yield 2027 * -
1 day-0.12%
1 week-4.34%
Current month-5.81%
1 month-11.18%
3 months-8.58%
6 months-21.76%
Current year-16.22%
1 week 41.11
Extreme 41.11
43.56
1 month 41.11
Extreme 41.11
49.82
Current year 41.11
Extreme 41.11
59.68
1 year 41.11
Extreme 41.11
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 64 22/12/2005
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/8/26 Exercice

Chief Technology Officer

4,097 0.0073%
12/8/26 Exercice

Chief Financial Officer

3,104 0.0055%
12/8/26 Exercice

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%-4.34%-10.76%+39.83% 2.42B
-0.54%-4.26%+69.03%+32.53% 355B
-0.15%-3.24%+21.83%-20.33% 66.33B
+0.19%-2.71%+38.27%+185.87% 12.17B
-0.66%-8.82%-11.70%-16.24% 7.47B
-4.80%-8.31%-28.14%-8.74% 4.64B
+0.63%-2.46%-33.22%+4.34% 4.42B
-1.24%-6.98%-34.91%-13.14% 2.86B
-1.84%-5.00%-28.35%-23.61% 1.9B
-2.01%-2.36%-26.38%-17.27% 1.66B
Average -1.05%-4.31%-4.43%+16.32% 45.9B
Weighted average by Cap. -0.51%-4.14%+56.30%+26.82%

Financials

2026 *2027 *
Net sales 886M 763M 723M 655M 1.23B 84.62B 1.24B 8.58B 3.3B 43.05B 3.33B 3.25B 136B 1.37B 1.18B 1.12B 1.01B 1.9B 131B 1.91B 13.29B 5.11B 66.67B 5.15B 5.04B 211B
Net income -11.54M -9.95M -9.42M -8.54M -16.01M -1.1B -16.1M -112M -43.01M -561M -43.36M -42.4M -1.77B 71.54M 61.64M 58.37M 52.9M 99.25M 6.83B 99.75M 693M 267M 3.48B 269M 263M 10.99B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
11/09/26 USD 41.64 -0.12% 707,159
10/09/26 USD 41.69 -0.90% 726,749
09/09/26 USD 42.07 -0.85% 580,434
08/09/26 USD 42.43 -2.53% 429,133
04/09/26 USD 43.53 -1.00% 444,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
41.64USD
Average target price
61.75USD
Spread / Average Target
+48.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!